Barzuxetan, also known as p-CHX-A-benzyl-DTPA, is a useful agent to make bioconjugates such TABITUXIMAB BARZUXETAN (OTSA-101-DTPA). Barzuxetan structurally contains a reactive functional group isothiocyanate and a ligand DTPA. The isothiocyanate group can easily react with the amino group (lysine residue) of the monoclonal antibody to form bioconjugates. The ligand DTPA can bind radio metal ions such as indium In 111, which is a gamma-emitting isotope. The radio-labeled conjugates may be used to detect FZD10-expressing tumor cells upon gamma scintigraphy. Upon administration of indium In 111 tabituximab barzuxetan, tabituximab targets and binds to FZD10 expressed on tumor cells. This allows for visualization of FZD10-expressing tumor cells upon gamma scintigraphy. FZD10, a member of the Frizzled family of G protein-coupled receptors, is one of the components in the Wnt/beta-catenin signaling pathway that plays key roles in embryogenesis and cancer growth.
MedKoo Cat#: 535011
Name: Barzuxetan
CAS#: 157380-45-5
Chemical Formula: C26H34N4O10S
Exact Mass: 594.1996
Molecular Weight: 594.64
Elemental Analysis: C, 52.52; H, 5.76; N, 9.42; O, 26.91; S, 5.39
The following data is based on the product molecular weight 594.64 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
